Patient monitoring stocks beat Q1 revenue estimates by 2.3% but guidance disappoints

Earnings
โดย Yahoo Finance·Read original
Summary · why it matters

The four patient monitoring stocks tracked by this review reported a strong first quarter, with aggregate revenues beating analysts' consensus estimates by 2.3%, though next quarter's revenue guidance came in 0.8% below expectations. Insulet led the group with revenues of $761.7 million, up 33.9% year on year and exceeding estimates by 4.2%, while also posting the fastest revenue growth and biggest analyst estimate beat. iRhythm Technologies reported revenues of $199.4 million, up 25.7% year on year and beating estimates by 2.8%, and delivered the highest full-year guidance raise among its peers. ResMed posted revenues of $1.43 billion, up 10.8% year on year and exceeding estimates by 0.8%, but recorded the weakest performance against analyst estimates and slowest revenue growth in the group. DexCom reported revenues of $1.19 billion, up 15% year on year and topping estimates by 1.4%, though it had the weakest full-year guidance update among its peers.

Impact on stocks 4

Biotech & Genomic Medicine▲ · 3 stocks
Insulet Corporation
PODD
▲ PositiveCapitalrelevance

Revenues beat estimates by 4.2% with 33.9% YoY growth, fastest in group.

DexCom Inc
DXCM
± MixedCapitalrelevance

Revenues beat estimates by 1.4% but full-year guidance update was weakest among peers.

Cloud & Digital Infrastructure▲ · 1 stocks
ResMed Inc
RMD
± MixedCapitalrelevance

Revenues beat estimates by 0.8% but had weakest performance vs estimates and slowest growth.

© 2026 MarketDXNews